X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
1st-line treatment (1) 1
anti-vegf therapy (1) 1
article (1) 1
biomarker (1) 1
cancer (1) 1
chemotherapy (1) 1
combination (1) 1
double-blind (1) 1
doxorubicin (1) 1
folfox (1) 1
hepatocellular carcinoma (1) 1
induction (1) 1
leucovorin (1) 1
oncology (1) 1
oxaliplatin (1) 1
phase ii (1) 1
sorafenib (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 4084 - 4084
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 80 - 89
Purpose: Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median... 
1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | DOXORUBICIN | DOUBLE-BLIND | OXALIPLATIN | INDUCTION | COMBINATION | ANTI-VEGF THERAPY | CANCER | CHEMOTHERAPY | phase II | Hepatocellular carcinoma | sorafenib | FOLFOX | biomarker
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 270 - 270
270 Background: Sorafenib is the standard first line treatment for advanced HCC and showed a median time to progression (TTP) of 5.5 months and an overall... 
Journal Article
Transcultural Psychiatry, ISSN 1363-4615, 9/1990, Volume 27, Issue 3, pp. 165 - 196
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.